VSEEVSee Health, Inc.
Is VSee Health struggling financially?
Yes, by its own account. VSee Health told the SEC on 15 May 2026, in Form 10-Q, that there is substantial doubt about its ability to continue as a going concern.
Going concern disclosed May 2026
11/100
Critical
- Sector
- Biotech/Pharma
- Source filing
- 10-Q 15 May 2026
- Balance sheet
- 30 Jun 2026
Cash runway
-
0months
If the burn speeds up
Empty by Jun 2026
-
1month
If it eases off
Empty by Jul 2026
Both rows are the same reported burn flexed 15% either way, and neither assumes the company raises a cent.
Out of cashTwo years or more
The runway math
Cash and short-term investments
$454K
÷
Cash burned over the last 12 months
$9.7M
What VSee Health told the SEC
…a loss from operations of $ 2,600,262 . The Company’s operations have been funded principally through the issuance of debt and equity. These factors raise substantial doubt about the Company’s ability to continue as a going concern for a period of one year from the issuance of these financial statements.
VSee Health, Inc., Form 10-Q, filed 15 May 2026.
Read the filing on SEC.govWhat this means
- Not a bankruptcy filing, and not a prediction.
- It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
- The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.
What else the numbers show
- 213.3% share-count increase The company issued stock. Each share now owns 68.1% less of the business than a year ago, before any change in the price.
- Cash burn is increasing It is spending 37% more cash per year than it was, so the runway above shortens even if nothing else changes.
- Debt pressure is material Operating earnings cover only -302.3x the interest bill, so the interest is being met out of cash reserves rather than out of the business.
Other Biotech/Pharma companies that filed the doubt
- ENSC Ensysce Biosciences $7.3M
- PHGE Biomx $3.7M
- FEMY Femasys $24.8M
- ALZN Alzamend Neuro $7.5M
- HCWB HCW Biologics $4.0M
- SHPH Shuttle Pharmaceuticals Holdings $3.9M